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The noninvasive nature of the detection of fetal DNA in the maternal circulation represents the greatest
advantage over the conventional methods of prenatal diagnosis. The applications of this methodology involve
the detection of the fetal sex, and diagnosis, intra-uterine treatment, and evaluation of the prognosis of many
diseases. Fetal cells detected in the maternal circulation have also been shown to be implicated in autoimmune
diseases and to represent a potential source of stem cells. On the other hand, with the introduction of a
technology that detects the fetal sex as early as at 6-8 weeks of gestation, there is the possibility of early
abortion based on sex selection for social purposes. This implies an ethical discussion about the question. The
introduction of new noninvasive techniques of prenatal diagnosis and the knowledge of the Nursing Team
regarding new methodologies can be of great benefit to the mother and her children, and can help the Genetic
Counseling of the families.
DESCRIPTORS: prenatal diagnosis; DNA; blood; stem cells; blood group incompatibility; sex; eclampsia;
epigenesis, genetic; ethics
DNA FETAL LIBRE EN EL PLASMA MATERNO Y DIAGNÓSTICO PRENATAL NO INVASIVO
La naturaleza no invasiva de la investigación del DNA fetal en la circulación materna representa una
ventaja importante con relación a los métodos convencionales de diagnóstico prenatal. El uso de esta metodología
implica la determinación del sexo fetal y el diagnóstico, el tratamiento intra-útero y la evaluación del pronóstico
en muchas enfermedades. Las células fetales detectadas en la circulación maternal también pueden ser
implicadas en enfermedades autoinmunes y representar una fuente potencial de células madre. Por otra parte,
con la introducción de una tecnología que detecte el sexo fetal entre 6-8 semanas de gestación, existe la
posibilidad de aborto precoz basada en la selección del sexo para los propósitos sociales. Esto implica una
discusión ética previa sobre este problema. La introducción de nuevas técnicas no invasivas de diagnóstico
prenatal y el conocimiento del Equipo de Enfermería con respecto a las nuevas metodologías pueden ser muy
importantes a la madre y a sus niños, y ayudar al Consejo Genético de las familias.
DESCRIPTORES: diagnóstico prenatal; ADN; sangre; células madre; incompatibilidad de grupos sanguíneos;
sexo; eclampsia epigénesis genética; ética
DNA LIVRE FETAL EM PLASMA MATERNO E DIAGNÓSTICO PRÉ-NATAL NÃO INVASIVO
A natureza não invasiva para o feto da pesquisa de DNA fetal em circulação materna representa sua
maior vantagem sobre os métodos convencionais de diagnóstico pré-natal. As aplicações desta metodologia
envolvem a detecção do sexo fetal e o diagnóstico, tratamento intra-útero e avaliação do prognóstico de
várias doenças. Já as células fetais detectadas em circulação materna podem estar envolvidas em doenças
auto-imunes e representar uma fonte de células-tronco para as mães. Com a introdução comercial de uma
técnica que detecta o sexo fetal entre 6-8 semanas, haveria o risco de abortos precoces devido à seleção do
sexo por propósitos sociais, tornando necessária uma discussão prévia sobre os aspectos éticos desta questão.
A introdução de novas técnicas não invasivas de diagnóstico pré-natal e o conhecimento das mesmas por
parte da Equipe de Enfermagem poderão trazer grandes benefícios para a mãe e seus filhos, bem como
auxiliar no Aconselhamento Genético das famílias.
DESCRITORES: diagnóstico pré-natal; DNA; sangue; células-tronco; incompatibilidade de grupos sanguíneos;
sexo; eclampsia; epigênese genética; ética
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All pregnant women have the potential risk
to present an embryo with anomalies. Therefore,
maternal age should be taken into consideration in all
pregnancies and fetal morphologic ultrasonography and
biochemical tests in maternal blood should always be
carried out(1). However, in special cases, there is the
need to use invasive methods, such as chorionic villus
sampling (CVS) or amniocentesis, which represents a
higher risk for the embryo(2). For this reason, the
technologies involving prenatal diagnosis continue to
evolve, with emphasis on research for the development
and improvement of noninvasive techniques.
FETAL CELLS IN THE MATERNAL
CIRCULATION
The detection of fetal cells in maternal lung
parenchyma associated with eclampsia has been
described since the 19th century(3), but the presence
of these cells in maternal peripheral blood continues
to be the subject of intense research. Fetal cells appear
early in the maternal circulation during the first
trimester and continue to be present throughout
gestation. However, the isolation of fetal cells from the
maternal circulation is still technically complex. Fetal
cells can be present in maternal blood at a ratio of
1:100,000 maternal cells or less (or approximately one
per ml of maternal blood in euploid pregnancies)(4).
Another problem, in addition to their small numbers,
is the permanence of fetal cells in maternal circulation
after the pregnancy. There is a report of the detection
of nuclear male DNA in a woman who had her last son
27 years before the study(5). Other investigations have
shown that the persistent cells could have an important
role in women’s autoimmune diseases. On the other
hand, these cells appear to have stem cell
characteristics, such as the ability to proliferate and
differentiate, which could be of benefit to the mothers(4).
CELL-FREE FETAL DNA IN MATERNAL
PLASMA
The quantitative analysis of the free fetal DNA
demonstrated that this can compose up to 6.2% of
the total DNA present in the maternal plasma(6).
Apoptosis would partially explain the disappearance
of fetal DNA from maternal circulation after birth, since
this is a fast reaction, concluded within 2 to 3 hours
after childbirth. These results (a higher ratio in relation
to the maternal material and a faster disappearance
from the maternal circulation) demonstrate practical
superiority of the search for fetal DNA in maternal
plasma in relation to the preparation of fetal cells
isolated from maternal whole blood(4, 7).
APPLICATIONS
Many genetic diseases are caused by
mutations that result in subtle differences between
the sequences of maternal and fetal DNA, such as
achondroplasia(8) and â-thalassaemia(9). Many other
clinical applications, especially for single gene
disorders, have been described. We will discuss some
applications that are important because of their
incidence in the population.
Fetal Sexing
Most research groups use sequences of
chromosome Y in male embryos as a marker of fetal
DNA and standardization of the techniques, due to
the fact that a normal woman/mother (46,XX) does
not possess this chromosome in her genome. Sexing
is also important, mainly for diseases with a recessive
X-linked pattern of inheritance, with girls being normal
or being carriers of the mutation, but healthy, while
boys are normal or affected by the disease. Some
authors have used the polymerase chain reaction
(PCR) and amplification of Y-specific sequences,
mainly highly repetitive sequences or genes like
SRY(10). More recently, the TSPY gene has also been
used in studies of small DNA samples(11-12).
Another application of fetal sexing is
Congenital Adrenal Hyperplasia (CAH), a disease of
genetic origin with an autosomal recessive pattern of
inheritance. The most common defect is 21-
hydroxylase deficiency. Homozygous girls for the
deficiency are born with masculinization of the external
genitalia, many times requiring surgical correction.
The affected boys present normal external genitalia.
Prenatal treatment of CAH with dexamethasone to
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prevent genital ambiguity has been successfully
used(13). However, to minimize the side effects, the
interruption of therapy has been indicated in the case
of affected or normal male embryos and normal
female embryos. For this reason, fetal sexing is
necessary during pregnancy and is generally carried
out by invasive methods. Noninvasive fetal sexing
based on free fetal DNA in maternal plasma would
bring the additional advantage of early discontinuation
of medication in the case of male embryos(10).
Rh alloimmunization
Rh alloimmunization is a very important
problem in medical and obstetrical clinical practice,
potentially leading to hemolytic disease of the
newborn. For pregnant negative Rh patients (15% of
the population), a positive Rh embryo involves a 16%
risk of sensitization to the Rh antigen. Diagnostic
procedures and invasive therapy may be necessary
to reduce perinatal mortality of positive Rh
embryos(14). Thus, the early detection of fetal RhD
status through fetal DNA in the plasma of negative
Rh mothers is of great importance in defining the need
for interventions, with known risks of gestational loss,
or of gestational immunoprophylaxis.
Pre-eclampsia
Pre-eclampsia is characterized by an increase
in arterial pressure and proteinuria after the 20th
week of pregnancy. Its potential complications, such
as eclampsia, represent one of the most serious
problems for maternal and fetal health. According to
some authors, there is an increase of fetal DNA in the
blood of women with pre-eclampsia in comparison
with control groups. The increase in the rates of
circulating fetal and maternal DNA would correspond
to the degree of severity of the illness and, therefore,
the level of fetal DNA may serve as a marker of the
prognosis and severity of the clinical picture(7,15).
Although most researchers use the Y-chromosome in
this specific application, other non-gender markers
have been studied, including epigenetic markers, to
improve the number of pregnant women that could
be submitted to quantitative investigation(16).
DISCUSSION AND CONCLUSION
Due to the significant risk of invasive prenatal
diagnosis, there has been an intensive search for
noninvasive techniques of fetal DNA sampling. The
detection of fetal cells in the maternal circulation has
shown implications in autoimmune diseases and their
potential as a source of stem cells for the mothers.
However, the methodology available to search for
these cells is expensive and complex, due to the
permanence of fetal cells in the maternal circulation
after pregnancy and their scarcity. In contrast, the
isolation of cell-free fetal DNA from maternal plasma
is relatively easy and inexpensive and allows for the
simultaneous processing of many samples.
The technique of fetal sexing from maternal
blood can be useful for the standardization of the
methodology and in cases of diseases with a
recessive X-linked pattern of inheritance, where only
boys would be affected. Intrauterine detection could
also lead to an early and optimized treatment of
diseases in this group and of other illnesses such
as CAH. On the other hand, one problem in
introducing a technology that detects fetal sex as
early as 6-8 weeks of gestation is the possibility of
abortion based on sex selection for social purposes.
This may occur due to the possible greater
psychological and moral acceptability of an earlier
interruption of pregnancy. In Brazil, a couple of
services perform fetal sexing commercially, using
maternal blood. This implies an ethical discussion
about the question.
The early detection of fetal RhD status would
be highly useful in gestations of negative Rh
patients. Besides the importance of the qualitative
methods for many other genetic diseases, the
quantification of fetal DNA in the maternal circulation
seems to be a potential marker of prognosis in pre-
eclampsia.
As described by another group, the pregnant
women may be interviewed and the sample blood
can be taken in their homes by a nurse(17). The
introduction of new noninvasive techniques of prenatal
diagnosis and the nursing team’s knowledge about
new methodologies for patient orientation can be of
great benefit to mothers and children, and can help
the genetic counseling of families.
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